游离和纳米制剂地拉罗司治疗乳腺癌的潜在抗癌效果：体外和体内评估

IF 2.4 4区医学 Q3 CHEMISTRY, MEDICINAL

Drug Development and Industrial Pharmacy Pub Date : 2024-02-02 DOI:10.1080/03639045.2024.2314189

Nadeen Diaa Abdel-Wahab, Mohamed Fawzi Kabil, Ibrahim M. El-Sherbiny, Mohamed F. Salama, Gehad El-Sayed, El-Said El-Sherbini

引用次数: 0

摘要

背景：乳腺癌（BC）是导致全球妇女死亡的第二大原因。许多治疗乳腺癌的化疗方法都会产生严重的不良反应。此外，BC...

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Potential Anticancer Effect of Free and Nanoformulated Deferasirox for Breast Cancer Treatment: In-vitro and In-vivo Evaluation

Background: Breast cancer (BC) stands as the second leading cause of mortality among women worldwide. Many chemotherapeutic treatments for BC come with significant adverse effects. Additionally, BC...

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Drug Development and Industrial Pharmacy 医学-药学

CiteScore

6.80

自引率

0.00%

发文量

审稿时长

4.5 months

期刊介绍： The aim of Drug Development and Industrial Pharmacy is to publish novel, original, peer-reviewed research manuscripts within relevant topics and research methods related to pharmaceutical research and development, and industrial pharmacy. Research papers must be hypothesis driven and emphasize innovative breakthrough topics in pharmaceutics and drug delivery. The journal will also consider timely critical review papers.